Validation of an algorithm identifying relapses in multiple sclerosis using the French nationwide claims database

Pauline Bosco-Lévy1,2, Patrick Blin1, Séverine Lignot1, Régis Lassalle1, Abdelilah Abouelfath3, Pauline Diez-Andreu1, Marc Debouverie4, Bruno Brochet5, Céline Louapre5, Olivier Heinze6, Elisabeth Maillard2, Nicholas Moore3,4, Cécile Droz-Perrettauc1

1,2 Bordeaux PharmacoEpi, Univ. Bordeaux-INSERM UCB1410, Bordeaux, France; 3 Bordeaux Population Health Research Centre, INSERM UMR 1219, Univ. Bordeaux, Bordeaux, France; 4 CHU de Bordeaux, Bordeaux, France; 5 Department of Neurology, Nancy University Hospital, F-54405 Nancy, France; Université de Lorraine, EA 4360 APEMAC, F 54500 Vandoeuvre-Les Nancy, France; 6 CRIC SEF, service de Neurologie, CHU de Bordeaux, Bordeaux, France; 7 Biostatistics Unit, Institut de Cancérologie et de la Moelle épinière, ICM- Hépitaux de la Pitié-Salpêtrière, INSERM UMR S117, CHU Pitié-Salpêtrière, 75651, Paris, France

Background

- Multiple sclerosis (MS)
  - Inflammatory, progressive, chronic neurological disorder that involves a selective, chronic demyelination of the central nervous system
  - Relapsing-remitting MS form (RRMS) is the most common, and is characterized by the presence of relapses without disability progression between relapses
  - In France, prevalence in 2015: 135 per 100,000 inhabitants and 87,000 cases in 2017

- Relapses
  - Clinically defined as the occurrence of new neurologic symptoms or the recurrence of old neurological symptoms that last at least 24 hours
  - SINDS (national healthcare system database): No direct indicator available, complex algorithm based on: hospitalization(s) related to relapses or related to MS, or outpatient dispensation(s) of IV or oral high-dose corticosteroid therapy, or combination of hospitalization(s) related to relapse or related to MS and outpatient dispensation(s) of IV or oral high-dose corticosteroid therapy.

- Validation of the algorithm
  - Conducted by clinicians using all information of the database (as a patient's medical file, see below) for a random sample of patients

Objectives

- To assess the validity of an algorithm identifying relapses in MS patients in SINDS database

Methods

- Data source: extraction of SINDS data from 2011 to 2016 (EVIDEMS cohort)
- General approach
  1. Execution of the algorithm for relapses identification
  2. Assessment of randomly selected cases by a committee of experts
  3. Calculation of positive (PPV) and negative (NPV) predictive values of the algorithm
  4. Adjustment of algorithm
  5. Calculation of positive (PPV) and negative (NPV) predictive values of the algorithm

- SINDS data formatting for cases review (Figure 1)
  - For each case, pseudonymized medical chart was reconstructed using data of SINDS extraction:
    - age class, sex, drugs dispensing, hospitalization, medical procedures (during history period and follow-up period)
    - healthcare data possibly related to MS: the dispensing of corticosteroids, hospitalizations for potential MS relapse or for administration of high dose of steroids.

- Validation committee (Figure 2)
  - Random selection of 200 patients among 37,968 MS patients of the cohort: 100 MS patients with at least one relapse during follow-up period detected by the algorithm, 100 MS patients without relapse (not detected by the algorithm)
  - Double blind review of 100 patients (with at least one relapse and 50 without relapse) per expert pair
  - By 2 expert pairs (each pair with 1 neurological member of the Scientific Committee of EVIDEMS study + 1 independent neurologist)

- Algorithm validation (Figure 2)
  - Assessment by each expert of the presence or absence of relapses and the number of relapses
  - In case of discrepancy within a pair of experts: the case was discussed by the 4 experts to reach consensus
  - Algorithm performance was estimated using the positive and negative predictive values (PPV, NPV)

Results

- Inter-expert and algorithm discrepancy
  - Inter-expert discrepancy: among the 200 MS patients selected, the summary sheets of 35 patients were reviewed in a collaborative manner, in order to reach a consensus
  - Algorithm discrepancy: finally 10 discordant cases (9 patients because a patient may have many relapses) have been identified by the experts: 7 related to the criteria "relapse presence" and 4 to the criteria "relapse absence"

- PPV and NPV calculation (Table 1)
  - Confirmation of 95 out of 100 MS patients with at least one relapse and 96 out of 100 patients without relapse
  - PPV = 95.0% and NPV = 96.0%

Table 1. PPV and NPV calculation

<table>
<thead>
<tr>
<th>Algorithm</th>
<th>Relapse</th>
<th>Without relapse</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experts</td>
<td>95</td>
<td>4</td>
<td>100</td>
</tr>
<tr>
<td>Without relapse</td>
<td>5</td>
<td>96</td>
<td>101</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100</td>
<td>200</td>
</tr>
</tbody>
</table>

PPV and NPV calculation after algorithm adjustment (Table 2)

- Discrepancy cases have been discussed by the experts in order to adjust the algorithm
- Finally, the algorithm was revised to include all changes proposed by the experts
- The proposed changes increased algorithm performance: the PPV and NPV of the revised version of the algorithm became 95.2% and 100% respectively.

Table 2: PPV and NPV calculation after algorithm adjustment

<table>
<thead>
<tr>
<th>Algorithm</th>
<th>Relapse</th>
<th>Without relapse</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experts</td>
<td>99</td>
<td>5</td>
<td>104</td>
</tr>
<tr>
<td>Without relapse</td>
<td>0</td>
<td>96</td>
<td>96</td>
</tr>
<tr>
<td>Total</td>
<td>99</td>
<td>101</td>
<td>200</td>
</tr>
</tbody>
</table>

Conclusion

- The wealth of data available in the SINDS enables
  - The implementation of algorithms to detect complex events
  - The validation of these algorithms via the reclassification of pre-synthesized medical charts based on SINDS data

- This claim-based algorithm
  - Appeared to successfully detect MS relapses
  - Could thus be applied to future observations: MS studies in SINDS database such as those aiming to assess effectiveness of MS treatments on relapses

Declaration of Interest Statement: The validity assessment of this algorithm is linked to a study using it (EVIDEMS) and carried out by the Bordeaux PharmacoEpi platform in collaboration with Biogen and supervised by an independent scientific committee. The study was supported by an unconditional grant from Biogen.

36th ICPE International Society for Pharmacoepidemiology, September 17-18, 2020, Virtual event  
[Abstract # 3874]